← All Sponsors
SPONSOR

Monument Therapeutics Limited

Total Trials
1
Recruiting
1
Phases
Phase 1, Phase 2
Conditions studied: Clinical High Risk for Psychosis (CHR)
NCT07226895 Phase 1, Phase 2
Recruiting

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

Clinical High Risk for Psychosis (CHR)
United States View Trial →